<DOC>
	<DOCNO>NCT02430493</DOCNO>
	<brief_summary>The primary objective describe safety tolerability ticagrelor , assessment adverse event ( characteristic , report rate , severity , relationship risk factor ) , especially bleed event define 8.1 serious adverse event ( SAEs ) 1-year follow Chinese acute coronary syndrome ( ACS ) patient .</brief_summary>
	<brief_title>Evaluation Safety Ticagrelor Among Chinese ACS Patients</brief_title>
	<detailed_description>The trial multi-centre , prospective cohort , non-interventional study conduct department cardiology approximately 20 tier-2 3 hospital , China . The study require Chinese subject age 18 , diagnose ACS treat ticagrelor least one tablet department cardiology around 20 tier-2 3 hospital . The subject track 1 month discontinuation ticagrelor AE event 1 year enrollment major cardiovascular event . This observational study . The prescribe doctor charge prescribe discontinuation ticagrelor . The investigator observational study may intervene treatment . All 1000 subject ' relate data collect .</detailed_description>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>1 . Provision inform consent prior study specific procedures 2 . Chinese female male age least 18 year 3 . Index event nonST ST segment elevation ACS . 4 . Taken ticagrelor least one tablet enrollment . 1 . Participation another clinical study investigational product last 6 month . 2 . Previous enrolment present study ; 3 . Allergy contraindication ticagrelor describe ticagrelor China PI .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>ACS</keyword>
</DOC>